| Predicate |
Object |
| contentType |
Comparative Study|Journal Article |
| endingPage |
12 |
| issn |
1172-7047
1179-1934 |
| issueIdentifier |
1 |
| pageRange |
1-12 |
| publicationName |
CNS Drugs |
| startingPage |
1 |
| bibliographicCitation |
Walley T. Neuropsychotherapeutics in the UK: what has been the impact of NICE on prescribing? CNS Drugs. 2004;18(1):1–12. doi: 10.2165/00023210-200418010-00001. PMID: 14731055. |
| creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2df8749f6792654186f660bce9c0e313 |
| date |
200401 |
| identifier |
https://pubmed.ncbi.nlm.nih.gov/14731055
https://doi.org/10.2165/00023210-200418010-00001 |
| isPartOf |
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/22443
https://portal.issn.org/resource/ISSN/1172-7047
https://portal.issn.org/resource/ISSN/1179-1934 |
| language |
English |
| source |
https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
https://scigraph.springernature.com/ |
| title |
Neuropsychotherapeutics in the UK: what has been the impact of NICE on prescribing? |
| discusses |
http://id.nlm.nih.gov/mesh/M0021770 |
| discussesAsDerivedByTextMining |
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5070
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7025
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8532
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_efa31556fab5b1efdf7fd0827d809efa
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3081884 |